| Dr Jillian Lea Fortier, MD | |
|
263 Farmington Ave, Residency Administration- Ag093, Farmington, CT 06030-1921 | |
| (860) 679-2147 | |
| Not Available |
| Full Name | Dr Jillian Lea Fortier |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 14 Years |
| Location | 263 Farmington Ave, Farmington, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184945586 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| John Dempsey Hospital | Farmington, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Connecticut Health Center | 3678472016 | 523 |
News Archive
The coralberry could offer new hope for asthmatics: researchers at the University of Bonn have extracted a new kind of active pharmaceutical ingredient from its leaves to combat this widespread respiratory disease. In mice, it almost completely inhibits the characteristic contraction of the airways.
As National Allergy Awareness Month continues through the month of May, Puffs Facial Tissues is proud to announce their partnership with the Asthma and Allergy Foundation of America (AAFA). For years, people living with allergies have turned to Puffs to ease the discomfort of their seasonal allergy symptoms - such as annoying sniffles, watery eyes, frequent repeated sneezing - but this year they can expect even more from the tissue brand.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.
The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.
› Verified 1 days ago
| Entity Name | University Of Connecticut Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720083769 PECOS PAC ID: 3678472016 Enrollment ID: O20040106000105 |
News Archive
The coralberry could offer new hope for asthmatics: researchers at the University of Bonn have extracted a new kind of active pharmaceutical ingredient from its leaves to combat this widespread respiratory disease. In mice, it almost completely inhibits the characteristic contraction of the airways.
As National Allergy Awareness Month continues through the month of May, Puffs Facial Tissues is proud to announce their partnership with the Asthma and Allergy Foundation of America (AAFA). For years, people living with allergies have turned to Puffs to ease the discomfort of their seasonal allergy symptoms - such as annoying sniffles, watery eyes, frequent repeated sneezing - but this year they can expect even more from the tissue brand.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.
The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.
› Verified 1 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669466561 PECOS PAC ID: 8022915677 Enrollment ID: O20041122000596 |
News Archive
The coralberry could offer new hope for asthmatics: researchers at the University of Bonn have extracted a new kind of active pharmaceutical ingredient from its leaves to combat this widespread respiratory disease. In mice, it almost completely inhibits the characteristic contraction of the airways.
As National Allergy Awareness Month continues through the month of May, Puffs Facial Tissues is proud to announce their partnership with the Asthma and Allergy Foundation of America (AAFA). For years, people living with allergies have turned to Puffs to ease the discomfort of their seasonal allergy symptoms - such as annoying sniffles, watery eyes, frequent repeated sneezing - but this year they can expect even more from the tissue brand.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.
The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jillian Lea Fortier, MD 263 Farmington Ave, Farmington, CT 06030-0001 Ph: (860) 679-8080 | Dr Jillian Lea Fortier, MD 263 Farmington Ave, Residency Administration- Ag093, Farmington, CT 06030-1921 Ph: (860) 679-2147 |
News Archive
The coralberry could offer new hope for asthmatics: researchers at the University of Bonn have extracted a new kind of active pharmaceutical ingredient from its leaves to combat this widespread respiratory disease. In mice, it almost completely inhibits the characteristic contraction of the airways.
As National Allergy Awareness Month continues through the month of May, Puffs Facial Tissues is proud to announce their partnership with the Asthma and Allergy Foundation of America (AAFA). For years, people living with allergies have turned to Puffs to ease the discomfort of their seasonal allergy symptoms - such as annoying sniffles, watery eyes, frequent repeated sneezing - but this year they can expect even more from the tissue brand.
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.
The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.
› Verified 1 days ago
Zachary Tallent Solomon, Surgery Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-3467 | |
Jeffery Spiro, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-2100 Fax: 860-679-4815 | |
Brendan Gontarz, MD Surgery Medicare: Medicare Enrolled Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-3467 Fax: 860-679-1460 | |
Dr. Jeffrey Erwin Indes, MD Surgery Medicare: May Accept Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-8080 Fax: 860-679-1420 | |
Dr. David W Mcfadden, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, General Surgery, Farmington, CT 06030 Phone: 860-679-8080 Fax: 860-679-1420 | |
Peter Deckers, Surgery Medicare: Not Enrolled in Medicare Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-2100 Fax: 860-679-4815 |